In our study, the presence of FLT3‐ITD did not significantly affect CR probability or survival in the 24 positive patients, suggesting that CPX‐351 may be used for s‐AML and t‐AML patients harboring these mutations. This evidence concerns the gene FLT3 and acute myeloid leukemia.